Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity.

Mantle cell lymphomas (MCLs) are molecularly characterized by bcl-1 rearrangement and constant cyclin D1 (PRAD-1/CCND1) gene overexpression. Cyclin D1 is a G1 cyclin that participates in the control of the cell cycle progression by interacting with the retinoblastoma gene product (pRb). Inactivation of the Rb tumor suppressor gene has been implicated in the development of different types of human tumors including some high grade non-Hodgkin's lymphomas. To determine the role of the retinoblastoma gene in the pathogenesis of MCLs and its possible interaction with cyclin D1, pRb expression was examined in 23 MCLs including 17 typical and 6 blastic variants by immunohistochemistry and Western blot. Rb gene structure was studied in 13 cases by Southern blot. Cytogenetic analysis was performed in 5 cases. The results were compared with the cyclin D1 mRNA levels examined by Northern analysis, and the proliferative activity of the tumors was measured by Ki-67 growth fraction and flow cytometry. pRb was expressed in all MCLs. The expression varied from case to case (mean, 14.1% of positive cells; range, 1.3 to 42%) with a significant correlation with the proliferative activity of the tumors (mitotic index r = 0.85; Ki-67 r = 0.7; S phase = 0.73). Blastic variants showed higher numbers of pRb-positive cells (mean, 29%) than the typical cases (10%; P < 0.005) by immunohistochemistry and, concordantly, higher levels of expression by Western blot. In addition, the blastic cases also had an increased expression of the phosphorylated protein. No alterations in Rb gene structure were observed by Southern blot analysis. Cyclin D1 mRNA levels were independent of pRb expression and the proliferative activity of the tumors. These findings suggest that pRb in MCLs is normally regulated in relation to the proliferative activity of the tumors. Cyclin D1 overexpression may play a role in the maintenance of cell proliferation by overcoming the suppressive growth control of pRb.

[1]  F. Bosch,et al.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.

[2]  F. Bosch,et al.  PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. , 1994, Cancer research.

[3]  M. Dyer,et al.  BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. , 1994, Oncogene.

[4]  N. Harris,et al.  Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. , 1994, The American journal of pathology.

[5]  B. Coiffier,et al.  European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL) , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Bartek,et al.  DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1 , 1994, The Journal of cell biology.

[7]  J. Bartek,et al.  Cyclin D1 expression is regulated by the retinoblastoma protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  N. Takakura,et al.  PRAD1 gene over‐expression in mantle‐cell lymphoma but not in other low‐grade B‐cell lymphomas, including extranodal lymphoma , 1994, British journal of haematology.

[9]  S. Shurtleff,et al.  D-type cyclin-dependent kinase activity in mammalian cells , 1994, Molecular and cellular biology.

[10]  R. Weinberg,et al.  Function of a human cyclin gene as an oncogene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. C. Lucibello,et al.  Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. , 1994, Oncogene.

[12]  M. Tiemann,et al.  Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas. , 1994, Leukemia.

[13]  A. López-Guillermo,et al.  PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. , 1994, Blood.

[14]  C. Harris,et al.  Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Shurtleff,et al.  Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. , 1993, Genes & development.

[16]  F. Berger,et al.  Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. , 1993, Blood.

[17]  David M. Livingston,et al.  Functional interactions of the retinoblastoma protein with mammalian D-type cyclins , 1993, Cell.

[18]  R. Weinberg,et al.  Physical interaction of the retinoblastoma protein with human D cyclins , 1993, Cell.

[19]  M. Pagano,et al.  Cyclin D1 is a nuclear protein required for cell cycle progression in G1. , 1993, Genes & development.

[20]  M. Piris,et al.  Retinoblastoma (rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction , 1993, The Journal of pathology.

[21]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[22]  Steven K. Hanks,et al.  Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins , 1992, Cell.

[23]  R. Weinberg,et al.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins , 1992, Cell.

[24]  S. Pileri,et al.  Mantle Cell Lymphoma , 2022, The EBMT/EHA CAR-T Cell Handbook.

[25]  Y. Akao,et al.  Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. , 1992, Oncogene.

[26]  N. Harris,et al.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. Benedict,et al.  Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. , 1991, Oncogene.

[28]  A. Arnold,et al.  A novel cyclin encoded by a bcl1-linked candidate oncogene , 1991, Nature.

[29]  M. Raffeld,et al.  Inactivation of the retinoblastoma gene in human lymphoid neoplasms. , 1991, Blood.

[30]  J. Delabie,et al.  Translocation (11;14): A cytogenetic anomaly associated with B‐cell lymphomas of non‐follicle centre cell lineage , 1991, The Journal of pathology.

[31]  E. Jaffe,et al.  Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. , 1990, Blood.

[32]  E. Jaffe,et al.  Lymphocytic Lymphoma of Intermediate Differentiation: Morphologic and Immunophenotypic Spectrum and Clinical Correlations , 1990, The American journal of surgical pathology.

[33]  D. Weisenburger,et al.  Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings. , 1987, Blood.

[34]  Stephen H. Friend,et al.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.

[35]  Robert C. Leif,et al.  Convention on nomenclature for DNA cytometry , 1984 .

[36]  I W Taylor,et al.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[37]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[38]  C. Byus,et al.  Ribonucleic acid isolated by cesium chloride centrifugation. , 1974, Biochemistry.

[39]  É.,et al.  Genotypic Characterization of Centrocytic Lymphoma : Frequent Rearrangement of the Chromosome 11 bcl-1 Locus , 2022 .